Goflikicept is under clinical development by R-Pharm and currently in Phase III for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome. According to GlobalData, Phase III drugs for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome have a 7% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Goflikicept’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Goflikicept overview
Goflikicept is under development for the treatment of idiopathic recurrent pericarditis, Schnitzler syndrome, familial mediterranean fever (FMF), acute respiratory distress syndrome and coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is administered through subcutaneous route. The drug candidate is a fusion protein that acts by targeting IL-1beta/IL-1F2-induced signaling. It was also under development for Behcet’s disease.
RPH-104 was under development for the treatment of gouty arthritis (gout), pericarditis, myocardial infarction and adult-onset Still's disease (AOSD).
.
R-Pharm overview
R-Pharm (R Pharm) is a pharmaceutical company. It carries out the production of drugs, active pharmaceutical ingredients, laboratory equipment and high-tech medical systems. The company’s pipeline products include RPH-001, RPH-002, RPH-120, RPH-075, RS-113 and RS-110 for oncology; Nemonoxacin, Narlaprevir, Cefilavancin and Delamanid which targets antimicrobial; Olokizumab, Goflikicept, RPH-035 and Etanercept for anti-infammatory and products. Its therapeutic areas are oncology, nephrology, cardiology, virology and hepatitis, drug treatment, intensive therapy and others. The company collaborates with pharmaceutical and biotechnology companies. It has operations in Russia, the US, Azerbaijan, Uzbekistan, Kyrgyzstan, Kazakhstan, Belarus and Germany. R-Pharm is headquartered in Moscow, Russia.
For a complete picture of Goflikicept’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
